Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress
Celyad’s management will host a conference call at 2pm CEST / 8am EDT today
- Strong progress in THINK trial with very first signals of clinical activity in solid tumors
- Non-exclusive license agreement signed with Novartis
- Fresh licensing agreement reached with CAR-T technology inventors
- Strong central IP position in the allogeneic CAR-T field confirmed by USPTO